AmideBio
Boulder, United States· Est.
AmideBio leverages its in-silico design and peptide synthesis capabilities to develop a pipeline of peptide drug candidates that target metabolic disease.
Private Company
Total funding raised: $11.3M
About
AmideBio leverages its in-silico design and peptide synthesis capabilities to develop a pipeline of peptide drug candidates that target metabolic disease.
BiologicsAntibodies
Funding History
13Total raised:$11.3M
Grant$930K
Grant$1.4M
Seed$2.5M
Grant$1.3M